Navigation Links
Innovotech signs agreement for distribution of its bioFILM PA test in Israel
Date:8/12/2010

Edmonton, Alberta, July 27, 2010 Innovotech Inc. (TSX-V: IOT), a pioneer in the field of biofilm product development, has signed an exclusive distribution agreement with LevPharm Ltd of Israel to market and distribute its bioFILM PA test to hospitals and clinics within Israel.

"We are very excited to enter into this agreement with LevPharm, who recognize the significant impact the bioFILM PA test can have on improving patient care while reducing the cost burden to health care systems," said Ken Boutilier, President and CEO of Innovotech Inc. "The partnership with LevPharm illustrates their understanding of the importance of technologies for biofilm management, and further demonstrates Israel's leadership in embracing innovative products and solutions to enhance their health care system."

The current market capacity in Israel for acute infection treatment alone is estimated to be over 3,000 bioFILM PA tests per year.

bioFILM PA is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based Pseudomonas aeruginosa infections.

Pseudomonas aeruginosa is a common bacterium responsible for many hospital acquired infections including ventilator-associated pneumonia and those found in patients with burns and wounds. It is also one of the major causes of lung infections in individuals with Cystic Fibrosis.

Over eighty percent of microbial infections in the body are caused by organisms in a biofilm state. Biofilm infections are known to be up to 4,000 times more resistant to antibiotics than the same organism in a free-floating state, which demonstrates why it is so critical to identify effective treatments early, such as through the bioFILM PA test.


'/>"/>

Contact: Ken Boutilier
ken.boutilier@innovotech.ca
780-448-0585
Innovotech Inc.
Source:Eurekalert

Page: 1

Related biology news :

1. Innovotech receives funding to advance environmentally friendly agricultural crop protection product
2. Syngenta Crop Protection Canada announces seed treatment project with Innovotech
3. Eurofins MWG Operon signs contract to supply oligonucleotides to Research Councils
4. Signs of reversal of Arctic cooling in some areas
5. Lake sturgeon have genes from parasite, signs of human STD
6. Phosphorous in sodas and processed foods accelerates signs of aging say Harvard scientists
7. Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
8. Springer signs publishing agreement with ISOBM
9. Springer signs agreement with British Society of Research on Ageing
10. Copying mother natures designs
11. Plate-eating good: Université de Montréal professor designs edible tableware
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, Inc. ... on its oral peptide drug candidates, PTG-100 and ... the European Crohn,s and Colitis Organization (ECCO).  The ... Barcelona, Spain from February 15 – ... preclinical data on Protagonist drug candidates PTG-100 and ...
(Date:2/16/2017)... Ann Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... between 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 ... hosted by a MichBio member organization. They provide an opportunity to interact with peers, ...
(Date:2/16/2017)... MENLO PARK, Calif. and ... -- Longitude Capital, a private investment firm focused on ... today announced the promotion of Josh Richardson ... Richardson focuses on investments in biotechnology companies.  He ... and has played important roles in Longitude,s investments ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
Breaking Biology Technology: